Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 136 results for vitamins

  1. Dietary supplements:- Should people with coeliac disease be offered calcium and vitamin D supplements for a specific time period soon after their initial diagnosis?

    supplements:- Should people with coeliac disease be offered calcium and vitamin D supplements for a specific time period soon after...

  2. Vitamin D supplements in the management of CKD–mineral and bone disorders: In people with hyperparathyroidism secondary to CKD, does treatment with vitamin D or vitamin D analogues improve patient-related outcomes?

    Recommendation ID NG203/21 Question Vitamin D supplements in the management of CKD–mineral and bone disorders: In people with...

  3. Neonatal parenteral nutrition (QS205)

    This quality standard covers parenteral nutrition (intravenous feeding) for babies born preterm, up to 28 days after their due birth date, and babies born at term, up to 28 days after their birth. It describes high-quality care in priority areas for improvement.

  4. Atrial fibrillation (QS93)

    This quality standard covers identifying and managing atrial fibrillation (including paroxysmal, persistent and permanent atrial fibrillation, and atrial flutter) in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

  5. What type of training and awareness-raising can improve how health and social care practitioners: - promote vitamin D supplements among at-risk groups - improve the local population's awareness of, and attitudes towards, vitamin D supplements - uptake of vitamin D supplements?

    practitioners: - promote vitamin D supplements among at-risk groups - improve the local population's awareness of, and attitudes...

  6. Etelcalcetide for treating secondary hyperparathyroidism (TA448)

    Evidence-based recommendations on etelcalcetide (Parsabiv) for treating secondary hyperparathyroidism in adults with chronic kidney disease on haemodialysis.

  7. What is the best way of monitoring the local system for distributing vitamin D supplements?

    What is the best way of monitoring the local system for distributing vitamin D supplements? Any explanatory notes(if applicable) The...

  8. Nutrition support in adults (QS24)

    This quality standard covers care for adults (aged 18 and over) who are malnourished or at risk of malnutrition in hospital or in the community. It includes identifying people at risk of malnutrition and providing nutrition support, including dietary changes and artificial nutrition support given through feeding tubes (enteral nutrition) or directly into a vein (parenteral nutrition). It describes high-quality care in priority areas for improvement.

  9. How can a multiagency approach to improving awareness, availability and uptake of vitamin D supplements best be established, improved and sustained?

    multiagency approach to improving awareness, availability and uptake of vitamin D supplements best be established, improved and...

  10. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (TA249)

    Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.

  11. Dementia: target organ damage (all patients) (IND118)

    This indicator covers the percentage of patients with dementia (diagnosed on or after 1 April 2014) with a record of FBC, calcium, glucose, renal and liver function, thyroid function tests, serum vitamin B12 and folate levels recorded up to 12 months before entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM72

  12. Atrial fibrillation: diagnosis and management (NG196)

    This guideline covers diagnosing and managing atrial fibrillation in adults. It includes guidance on providing the best care and treatment for people with atrial fibrillation, including assessing and managing risks of stroke and bleeding.

  13. What is the clinical effectiveness and safety of vitamin D for treating COVID-19 in children, young people and adults?

    NG191/19 Question What is the clinical effectiveness and safety of vitamin D for treating COVID-19 in children, young people and adults?...

  14. Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)?

    Recommendation ID CG186/5 Question Can vitamin D slow down the progression of disability in Multiple Sclerosis (MS)? Any explanatory